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Evidence of Augmented Intrarenal Angiotensinogen Associated With
Glomerular Swelling in Gestational Hypertension and
Preeclampsia: Clinical Implications
Hiten D. Mistry, PhD;* Lesia O. Kurlak, PhD;* David S. Gardner, PhD; Ole Torffvit, MD, PhD; Alastair Hansen, MD, PhD;
Fiona Broughton Pipkin, DPhil; Helena Strevens, MD, PhD
Background-—AGT (angiotensinogen) synthesis occurs in renal proximal tubular epithelial cells, independent from systemic AGT, as
a component of the intrarenal renin–angiotensin system. We investigated urinary AGT, as a biomarker for renin–angiotensin system
activation, and electrolyte concentrations, in relation to glomerular volume, as a proxy for glomerular endotheliosis in renal biopsy
tissue from pregnant normotensive control and hypertensive women.
Methods and Results-—Urine samples were collected from normotensive control (n=10), gestational hypertensive (n=6), and pre-
eclamptic (n=16) women at the time a renal biopsy was obtained. Samples were collected from Lund University Hospital between
November 1999 and June 2001. Urinary AGT, potassium, and sodium were measured, normalized to urinary creatinine. Mean
glomerular volume was estimated from biopsy sections. AGT protein expression and localization were assessed in renal biopsies by
immunohistochemistry. Urinary AGT concentrations were higher in hypertensive pregnancies (median, gestational hypertension:
11.3 ng/mmol [interquartile range: 2.8–13.6]; preeclampsia: 8.4 ng/mmol [interquartile range: 4.2–29.1]; normotensive control:
0.6 ng/mmol [interquartile range: 0.4–0.8]; P<0.0001) and showed a positive relationship with estimated mean glomerular volume.
Urinary potassium strongly correlated with urinary AGT (P<0.0001). Although numbers were small, AGT protein was found in both
glomeruli and proximal tubules in normotensive control but was present only in proximal tubules in women with hypertensive
pregnancy.
Conclusions-—This study shows that pregnant women with gestational hypertension or preeclampsia have increased urinary AGT
and potassium excretion associated with signs of glomerular swelling. Our data suggest that the kidneys of women with
hypertensive pregnancies and endotheliosis have inappropriate intrarenal renin–angiotensin system activation, which may
contribute toward the pathogenesis of hypertension and renal injury. ( J Am Heart Assoc. 2019;8:e012611. DOI: 10.1161/
JAHA.119.012611.)
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T he renin-angiotensin system (RAS) was originallydescribed as a classical endocrine system, meaning
that hormones are produced by glands in one organ and have
remote effects elsewhere in the body after being transported
by the circulatory system.1 However, it is now known that
several tissues have autonomous or quasi-autonomous RAS,
among them the placenta and kidney.2,3 In the proximal
tubules of the kidney, all components of the RAS necessary
for Ang II (angiotensin II) synthesis (ie, renin, AGT [an-
giotensinogen], and ACE [angiotensin-converting enzyme]) are
present, together with the downstream effectors of RAS
activation, Ang II type 1 receptor (AT1R) and AT2R.4
During pregnancy, considerable homeorhetic responses are
activated to enable the expansion of blood volume during early
gestation that facilitates perfusion of the placenta and fetal
growth.5 To allow for such dynamic changes in circulatory
volume, concomitant adaptations are made in hormonal axes
that regulate blood volume, including the RAS, which is
activated in the first few weeks of pregnancy.6 The effects of
continuing progesterone synthesis by the corpus luteum after a
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conception cycle, if unchecked, would result in sodium loss
because of competitive binding to the structurally similar
aldosterone receptor MR (mineralocorticoid receptor). How-
ever, early sodium loss is recognized by the macula densa and
the RAS becomes activated, in turn stimulating adrenal cortical
synthesis of aldosterone and improved sodium retention.
Increased estrogen synthesis also stimulates hepatic AGT
synthesis. In addition, during pregnancy, Ang II itself further
enhances sodium retention through a direct action in the
proximal tubule. There, Ang II is able to mediate through AT1R
both increased uptake of circulating Ang II and augmentation of
AGT expression, which can lead to local formation of Ang II and
spillover of AGT excretion into the urine, where it can be
measured as a marker of intrarenal RAS activity. In addition,
renin secretion from principal cells of the collecting ducts can
be increased by AT1R activation, and the activity of renin and/
or prorenin can be enhanced by binding to the (pro)renin
receptor either on intercalated cells or in soluble form. All
described feed-forward mechanisms can, together, augment
intratubular and renal interstitial Ang II concentrations, con-
tributing to further renal vasoconstriction and sodium reab-
sorption.4 Consequently, maternal plasma volume increases
significantly from around 6 weeks’ gestation.
Normally, such extensive sodium retention would be
expected to be accompanied by a reciprocal increase in the
secretion of potassium, and a relative kaliuresis.7 However,
pregnant women cumulatively retain some 300 to 350 mEq of
potassium during normal pregnancy.8 There is a paucity of
data on potassium homeostasis during normal pregnancy,
let alone during pregnancies complicated by gestational
hypertension (GH). One early study suggested that the
kidneys of pregnant women become refractory to the
kaliuretic effects of increased RAS and estrogen, perhaps
due to an increased sensitivity to progesterone.9 To our
knowledge, no clinical studies have reported associations
between potassium homeostasis during pregnancy in women
with GH alone and/or in women with proteinuric GH
(preeclampsia).
Preeclampsia affects 2% to 8% of pregnant women
worldwide and is one of the top 3 causes of maternal
death.10 Perturbations of activity of the RAS in preeclampsia
have been noted for >50 years,11 but research into the role of
a dysfunctional RAS in preeclampsia has been limited. ACE
inhibitors are well-known teratogens in animal models12 and
in humans13,14 and are contraindicated in later pregnancy
because of their serious adverse effects on the fetus.15
Nevertheless, Zhou et al recently showed that oxidation of
circulating AGT is associated with increased generation of Ang
I,16 and the proportion of circulating oxidized AGT is increased
in pre-eclamptic pregnancies.16
A number of other mechanisms exist by which not only
circulating and/or local placental RAS but also an inappro-
priately activated intrarenal RAS could initiate or contribute to
the pathology of preeclampsia through, for instance, angio-
genic factors,17 the immune18 and coagulatory systems, and
the complement system.19
To date, no correlation between plasma and urinary AGT in
pregnant women has been shown, suggesting that autono-
mous regulation of the renal RAS occurs during pregnancy as
it does in the nonpregnant state. Urinary AGT has been shown
to reflect the rate of intrarenal synthesis and can be regarded
as a biomarker of intrarenal RAS activity20; levels of the
marker may also predict acute kidney injury and failure.21
In this study, for the first time, we examined urinary AGT,
sodium, and potassium in normotensive and hypertensive
pregnancies as a potential biomarker of intrarenal RAS
activity, related to glomerular swelling as a sign of endothe-
liosis. In a limited number of kidney biopsies from this
cohort,22 we confirmed the presence of intrarenal AGT by
immunohistochemistry. Evidence of an important role for the
inappropriate activation of intrarenal RAS in the pathophys-
iology of preeclampsia could indicate novel management and
postnatal therapeutic strategies and targets to prevent short-
term and long-term renal injury.
Methods
The data and analytic methods, but not study materials, will
be available to other researchers for purposes of reproducing
the results or replicating the procedure. Material is not freely
available because of the limited amounts and potential
degradation.
Sample Collection
Fully informed, signed consent for participation was obtained
from all women, as previously described,22 following the
Clinical Perspective
What Is New?
• To the best of our knowledge, this study is the first to
investigate, both functionally and histologically, intrarenal
angiotensinogen in normal and hypertensive human preg-
nancies.
What Are the Clinical Implications?
• Monitoring urinary angiotensinogen in preeclampsia as a
marker of an inappropriately activated renin–angiotensin
system might be a useful indicator of renal injury and its
progression both pre- and postpartum.
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ethics committee approval of the study by the University of
Lund, and all procedures involving the participants were in
accordance with the Helsinki Declaration of 1975. GH was
defined as diastolic blood pressure >90 mm Hg, determined
on >2 occasions >4 hours apart and arising after 20 weeks of
gestation. Preeclampsia was defined as for GH but also
including proteinuria (urine protein concentration >3000 mg/
L in 2 random clean-catch midstream specimens collected
≥4 hours apart). No woman had any known underlying renal
or hypertensive disease before 20 weeks’ gestation.
Overnight urine samples were taken 1 to 3 days before
renal biopsy in women with newly diagnosed GH admitted to
Lund University Hospital from November 1999 to June 2001.
All samples were collected before beginning antihypertensive
treatment. Healthy pregnant women with comparable gesta-
tional age who were recruited from maternal healthcare
centers in the catchment area of Lund University Hospital
provided overnight urine samples as controls. Samples with
evidence of urinary tract infection on urinalysis were excluded
from all analyses. All samples were stored at 80°C in
aliquots until analysis. Urine samples were available from 32
participants (10 normotensive controls, 6 women with GH,
and 16 pre-eclamptic women).
Renal biopsies were obtained as described previously.23
Briefly, biopsies were collected by an experienced radiologist
according to a standard procedure. The sample was taken
with a 1.2-mm (outside diameter) needle using a Bard biopsy
device under ultrasound guidance. Each biopsy, 20 mm in
length, was immediately submerged in 0.9% sodium chloride
solution and processed, with 1 part fixed in neutral formalde-
hyde 4% for immunohistochemical analysis.23
Biochemical Assays
Urinary AGT concentrations were measured in duplicate by
ELISA, following the manufacturer’s protocol. Urine samples
were diluted 1:10 using assay buffer. Intra- and interassay
coefficients of variation were 4.4% and 5.6%, respectively. The
mean urinary AGT concentration for each woman was
normalized to urinary creatinine. Urinary volume and crea-
tinine concentrations were measured in the Clinical Biochem-
istry Laboratory at Lund University by standard clinically
validated methods. Urinary potassium and sodium concen-
trations were measured by inductively coupled plasma mass
spectroscopy, as described previously, with specific stan-
dards.24,25 All analyses were conducted as blinded to
pregnancy outcome.
Glomerular Volume
Mean glomerular volume had been estimated previously in
biopsies containing at least 6 glomerular sections by a
computer-assisted stereological algorithm, as detailed previ-
ously.22
Immunohistochemical Analysis From Matched
Renal Biopsies
Only a limited amount of renal tissue remained from the
biopsies after previous evaluations and analyses,23 and sam-
ples were used opportunistically for a preliminary evaluation of
the immunohistochemical distribution of AGT within the
nephron. Three biopsies contained glomeruli (2–4), but no
biopsies contained sufficient vasculature for meaningful anal-
ysis. Protein expression in the kidney was analyzed by
immunohistochemistry using the Dako Envision staining kits,
as described previously,26 with rabbit anti-AGT (0.6 mg/mL;
HPA0031557 [Sigma Prestige]). For immunohistochemistry, a
semiquantitative scoring system was applied, as described by
Roy-Chaudhury et al.27 In brief, the scale was as follows: 0=no
specific staining, 0.5=very weakly positive, 1=weakly positive,
2=moderately strongly positive, 3=strongly positive. Scoring
was generally influenced by the extent rather than the intensity
of staining (ie, higher scores were given for widespread staining
as opposed to evidence of localized intense staining).
Statistical Analysis
Data were first assessed for distribution before analysis using
SPSS (v24; IBM Corp). Urinary data were not normally
distributed when all 3 groups (controls, GH, pre-eclamptic
pregnancies) were initially combined and thus are presented
as median (interquartile range [IQR]; 25–75% quartiles] unless
otherwise stated. Kruskal–Wallis nonparametric ANOVA was
used throughout the study, with the null hypothesis being
rejected at P<0.05. Linear correlations were computed using
Spearman q. The association of urine potassium with AGT
concentration was evaluated after log10 normalization. Curve
characteristics were determined by regression analysis
(GraphPad Prism, v6).
Results
Demographics of the Study Population
Table summarizes the basic demographic and pregnancy
outcome data.
Urinary AGT Assay
Urinary AGT was significantly elevated in hypertensive preg-
nancies compared with normotensive controls (in nanograms
of AGT per millimole of creatinine; normotensive control: 0.6
[IQR: 0.4–0.8]; GH: 11.3 [IQR: 2.8–13.6]; preeclampsia: 8.4
DOI: 10.1161/JAHA.119.012611 Journal of the American Heart Association 3
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[IQR: 4.2–29.1]; Kruskal–Wallis, P<0.0001; Figure 1). Post
hoc Mann–Whitney tests showed highly significant differ-
ences between normotensive controls and women with either
GH (P=0.002) and preeclampsia (P<0.0001). The difference
between women with GH and preeclampsia was not signif-
icant (P>0.3).
The patients’ blood pressures were measured at varying
times throughout pregnancy. We considered only the highest
recorded systolic and diastolic pressures for each patient in
relation to urinary AGT output at the time and during the days
of sampling. Regression analysis revealed highly significant
associations between log10 urinary AGT/creatinine and max-
imum systolic (r=0.623; P<0.0001) and diastolic (r=0.787;
P<0.0001) pressures. Furthermore, including log10 urinary
potassium/creatinine output in the analysis with diastolic
pressure significantly (P<0.02) improved r to 0.829, whereas
adding in urinary sodium/creatinine output was without
effect.
Table. Patient Demographics, BP, and Proteinuria and Urinary Sodium, Potassium, and Albumin Concentrations in NCs and Women
With GH or Preeclampsia
Parameter NC (n=10) GH (n=6) Preeclampsia (n=16)
Maternal age, y 29 (27–34) 28 (28–30) 30 (26–36)
BMI at booking, kg/m2 22.1 (21.3–22.3)*,† 25.9 (25.4–26.5)* 25.7 (24.3–30.3)†
After clinical diagnosis
Highest systolic BP 130 (120–130)*,† 145 (140–150)*,‡ 160 (160–180)†,‡
Highest diastolic BP 75 (75–85)*,† 110 (95–110)* 110 (107–118)†
Proteinuria, g/L  146 (84–251)‡ 931 (701–1814)‡
PCR, mg/mmol  13.2 (5.8–22.5)‡ 151.5 (77.3–270.9)‡
Gestation at delivery, d 281 (274–288)*,† 257 (254–265)‡ 244 (233–256)†
Birth weight, g 3655 (3430–3890)*,† 2935 (2865–3205)* 2630 (2030–2840)†
Sodium, mg/mmol 33.3 (30.3–65.4)*,† 325.1 (194.1–429.5)* 344.2 (168.6–471.4)†
Potassium, mg/mmol 18.9 (15.2–32.8)*,† 216.8 (194–292.2)* 222.9 (165.9–288.5)†
Albumin, mg/mmol 0.1 (0.02–0.2)*,† 10.1 (7.5–13.4)*,‡ 59.7 (29.3–176.8)†,‡
Data are presented as median (interquartile range) for continuous variables. Urinary parameters are normalized to creatinine levels. Groups were compared by Kruskall–Wallis. BMI
indicates body mass index; BP, blood pressure; GH, gestational hypertension; NC, normotensive control; PCR indicates protein:creatinine ratio.
*P<0.05 between NC and GH.
†P<0.05 between NC and preeclampsia.
‡P<0.05 between GH and preeclampsia.
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Figure 1. Urinary AGT (angiotensinogen) concentrations in normotensive control, gestational hyperten-
sive, and pre-eclamptic women. Data normalized to creatinine levels and presented as median (interquartile
range). *P<0.05; ***P<0.0001.
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Severity of preeclampsia is partly defined by the level of
proteinuria/albuminuria.28,29 Figure 2 shows a strong linear
association between albuminuria and urinary AGT (r=0.76;
P<0.0001) across the groups.
Urine Composition
Urinary sodium and potassium concentrations were
significantly higher in both hypertensive groups compared
with the normotensive controls (P<0.001 for all; Table).
Figure 3 shows a highly significant positive relationship
between urinary potassium concentration and AGT in all
groups (r=0.86; P<0.0001). No such association was
identified between urinary sodium concentration and AGT
(P>0.1).
Glomerular Volume Calculations
Glomerular volume estimation was available only for women
with GH (n=3) and preeclampsia (n=10). Figure 4 shows that
the higher glomerular volumes were associated with higher
urinary AGT, but the sample size was too small to allow
statistical analysis.
Immunohistochemical Analysis
Inevitably, only limited tissue blocks were available from the
previous study,23 and glomeruli were identifiable only in
sections from 3 patients: fortuitously, one was a normotensive
control, one had GH, and one had severe early onset
preeclampsia. As Figure 5A shows, AGT protein was widely
distributed throughout the glomerulus and in the proximal
tubules but not in the distal tubules in the normotensive control.
In contrast, Figure 5B2 and 5C2 show the absence of AGT
protein in glomeruli from the GH and preeclampsia patients,
although Figure 5B1 and 5C1 demonstrate AGT in the proximal
tubules. Proximal and distal tubules were identifiable in
sections from 9 normotensive controls, 6 patients with GH
(Figure 5B1), and 16 pre-eclamptic participants (Figure 5B2).
Staining at level 2 or 3was present in at least half of the sections
in which proximal tubules were identified in all groups; no
staining was observed in distal tubules from any patient.
Discussion
We have shown, for the first time, that urinary AGT—a marker
of activated intrarenal RAS—is significantly increased in
Figure 2. Scatterplot illustrating a strong positive relationship between urinary AGT (angiotensinogen)
concentrations and albuminuria (r=0.76; P<0.0001).
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women with both GH and preeclampsia. Although levels did
not significantly differ by type of hypertension, we found a
positive relationship with glomerular volume, indicating
glomerular endotheliosis. There were also strong associations
between urinary AGT and blood pressure across the study
group as a whole. Ang II is a potent systemic vasoconstrictor;
possible mechanisms linking intrarenal generation of Ang II
and blood pressure have been reviewed previously.30 A strong
association between urinary AGT and albumin excretion
(Figure 2) was also demonstrated, although a causative
relationship is impossible to determine from an observational
study. However, it has been shown that the infusion of Ang II
significantly increases albumin excretion in late-pregnant
spontaneously hypertensive rats.31 In nonpregnant humans,
increased RAS activity is associated with increased protein-
uria.32 Glomerular basement membrane “leakiness” might
allow the passage of both albumin (molecular weight:
66.5 kDa) and AGT (molecular weight: 62 kDa). However,
kidney podocytes, which form a filtration barrier against
protein loss, are functionally disorganized in glomerular
disease and in vitro by Ang II. Blockade of Ang II receptors
in nonpregnant animal models of nephropathy results in
improved function through reduced methylation of the nephrin
promoter and decreased proteinuria.33 Human studies, both
in vitro and observational, also suggest an intrarenal role for
Ang II in proteinuria.34
Renin was first identified as an enzyme synthesized in the
kidney, which was thought to be the only site of production
until other autonomous and tissue-specific RASs were
discovered >50 years ago.35 AGT, the substrate for renin, is
primarily synthesized in the liver, but mRNA for AGT has been
identified at other sites, including the renal tubule.36 In the
kidney, renin is released in response to physiological stimuli
that normally activate the RAS, such as a decrease in tubular
delivery of sodium chloride to the macula densa. Ordinarily,
although the reaction of renin with AGT is rate limited by renin
concentration, following first-order kinetics, sufficient circu-
lating concentrations of AGT (which are close to the Michelis–
Menten constant for the reaction37) prevent any such
limitation being reached. However, under circumstances that
result in longer term RAS activation, such as treatment with
estrogen-based contraceptives or during pregnancy, AGT may
become rate limiting.38 By 11 weeks’ gestation, an additional
high-molecular-weight form of AGT is identifiable in the
plasma of pregnant women.39 Moreover, the proportion of
high-molecular-weight AGT to normal AGT is also increased in
Figure 3. Scatterplot illustrating a clear positive relationship between urinary AGT
(angiotensinogen) and potassium in all groups collectively (r=0.86; P<0.0001). Data normalized
to creatinine levels and presented in log scale.
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women who develop pregnancy-associated hypertension,40
suggesting a means by which continued RAS activation might
underpin GH.
AGT formed locally in the kidney in proximal tubular cells
can spill over into the tubular lumen and be excreted in urine,
where it can be measured as an indicator of internal RAS
activity.41 ACE, which is responsible for the conversion of Ang
I to Ang II, exists both bound to vascular endothelial cells and
in a circulating form, allowing for both local and systemic
generation of Ang II. ACE is also present in renal proximal
tubules,4 confirming the plausibility of a renal RAS tailoring
local generation of Ang II and capable of fine-tuning intrarenal
sodium reabsorption independent of the classical systemic
RAS. This concept is supported by the observation that
sodium depletion in Wistar Kyoto rats enhances renal AGT
mRNA expression without a parallel change in renin expres-
sion.42 Intrarenally generated Ang II, by binding to AT1R, can
cause direct renal vasoconstriction, altering tubuloglomerular
feedback and increasing proximal tubular sodium reabsorp-
tion.43,44 AT1R-mediated uptake of circulating Ang II and
augmentation of AGT expression in proximal tubular cells
further augments intrarenal Ang II concentration and function,
as does the AT1R-mediated renin secretion from collecting
ducts.41
Investigations of a role for the intrarenal RAS and, in
particular, for AGT during pregnancy are in their infancy,3
although many roles both in pregnancy and preeclampsia
have been suggested for the placental and circulating RAS.45
Ang II has a variety of roles in the body; not only is it one of
the most potent circulating vasoconstrictors known, it also,
paradoxically, stimulates synthesis and/or release of the main
tonic vasodilator nitric oxide. Ang II promotes sodium
resorption, both directly across the proximal tubule and
indirectly by activating aldosterone, and stimulates vasculo-
genesis and angiogenesis, among other effects.46 The role of
circulating RAS in preeclampsia remains controversial, how-
ever, and its suppression has been demonstrated in estab-
lished hypertensive diseases of pregnancy (eg47). Sensitivity
to exogenous Ang II is reduced in normotensive pregnancy but
remains high in pre-eclamptic women,48,49 whereas sensitivity
to other vasoconstrictors remains unchanged. This difference
is apparent before the onset of preeclampsia.50
The finding of a strong association between urinary
potassium and AGT excretion is shown in Figure 3. Ang II
Figure 4. Scatterplot illustrating the positive relationship between urinary AGT (angiotensino-
gen) concentrations and estimated mean glomerular volume (lm3) in biopsies containing at least
6 glomerular sections, previously measured by a computer-assisted stereological algorithm.22
Sample size was too small for statistical analysis.
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stimulates aldosterone synthesis and thus distal tubular
sodium retention in exchange for potassium; therefore,
potassium excretion rises. In normal pregnancy, the RAS is
activated early; plasma aldosterone rises and some 950 mEq
of sodium are retained,8 much of which is associated with the
increase in plasma volume needed for the normal progress of
pregnancy. However, the pregnant woman also retains some
450 mEq of potassium, although the mechanism for this has
not yet been identified. In hypertensive pregnancy, plasma
volume expansion is reduced.51 Global overexpression of AGT
in transgenic mice was associated with a fall in plasma
volume from midpregnancy.52 Although data from animal
A
B1 B2
C1 C2
Figure 5. Immunohistochemical staining (9200 magnification) analysis of AGT (angiotensinogen) in
kidney biopsies. A, Healthy control. Strong cytoplasmic staining (score: 3) is seen in >50% of proximal tubuli
(asterisks in lumen) and, similarly, strong cytoplasmic staining (score: 3) in glomerular mesangium (arrow).
A small distal tubule/collecting duct shows no staining (score: 0; above arrow head). B, Patient with
gestational hypertension. (B1) Strong cytoplasmic staining (score: 3) is seen in >70% of proximal tubuli
(asterisk in lumen). (B2) Two glomeruli are present showing no expression (arrows). C, Patient with severe
preeclampsia. (C1) Strong cytoplasmic staining (score: 3) is seen in >70% of proximal tubuli (asterisk in
lumen). (C2) One glomerulus is present showing very weak cytoplasmic staining (score: 0.50) in the
mesangial area (arrow).
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models must be viewed with caution, these data suggest the
intriguing possibility that there may be prepregnancy or early
pregnancy differences in the RAS that predispose a woman to
developing preeclampsia. It follows that the increased renal
synthesis of AGT that we report here in hypertensive pregnancy
could be a response to relative hypovolemia in these women,
although this was not measured in our study. Increasing dietary
potassium intake in healthy volunteers has been associated
with a fall in urinary AGT excretion.53 Due to limitations in
sample size we were not able to compare fractional clearance
of sodium and potassium in women with preeclampsia in this
material, although it has been reported that renal hemody-
namic measurements are on average 25% to 30% lower in
women with preeclampsia than in gestation age–matched,
healthy, normotensive pregnant women.54 The urinary renin
concentration is known to be low.20,55 Stored volumes of urine
were too small to allow renin to be measured in this study.
In the limited amount of renal tissue that remained from
biopsies after previous investigations,23 we opportunistically
chose to demonstrate the presence of renal AGT expression
by immunohistochemistry. We showed that in human preg-
nancy, AGT expression seems to be confined to the proximal
tubule; no staining was demonstrated in any distal tubular
segment. This result was also shown in biopsy material from
nonpregnant patients,56 mice,52 and rats.43 The complete
absence of glomerular AGT staining in hypertensive preg-
nancy, in contrast to normotensive control, is of interest and
worthy of further study in appropriate animal models.
Measures of mean glomerular volume were available for 13
hypertensive women, having been estimated stereologically in
renal tissue. Larger glomeruli were found in women with
higher urinary AGT excretion, as shown in Figure 4. Glomeru-
lar volume is known to be increased in proportion to the
severity of preeclampsia.57 The glomerular endotheliosis of
preeclampsia has been ascribed to a decrease in circulating
VEGF (vascular endothelial growth factor), itself a conse-
quence of increased soluble Flt-1 (fms-like tyrosine kinase
1).58 Ang II stimulates soluble Flt in response to placental
ischemia in rats.17 Ang II immunostaining in glomeruli has
been shown in renal biopsies of patients with chronic kidney
disease, in whom an association between urinary AGT and
proteinuria also was noted.59 In these samples, we observed a
strong positive correlation between urinary AGT and albumin-
uria (Figure 2), presumably due to podocyte and glomerular
endothelial damage disrupting the filtration barrier of both.
There are a number of mechanisms by which an inappro-
priately activated intrarenal RAS could initiate or contribute to
the pathology of preeclampsia, for instance through angio-
genic and antiangiogenic factors,45 the immune system,18 and
coagulation systems and the complement system.19 An
activated complement system has been implicated in the
pathophysiology of preeclampsia by an increasing body of
evidence and can play a major role in causing renal injury also
in other complement-mediated renal diseases.19,60 Renin can
cleave C3 into C3a and C3b, thus activating the complement
system by this alternative pathway.60 Targeting excessive
complement activation has been suggested as a possible
therapeutic strategy in prevention or treatment of preeclamp-
sia19 and might also prevent long-lasting damage to the
kidney. Nevertheless, the risk of disrupting homeostatic
functions and host defense cannot be disregarded.
Women with a history of preeclampsia have not only a 2-
fold increased risk of developing long-term cardiovascular
disease but also a 5- to 12-fold increased risk of developing
end-stage renal disease,61 and there is need for renoprotec-
tive strategies to reduce late disease burden. In a paper
highlighting the fact that World Kidney Day and International
Women’s Day coincided in 2018,62 the World Kidney Day
Steering Committee emphasized that chronic kidney disease
affects 10% of the world’s adult population and takes place
among the top 10 causes of death worldwide. With the
knowledge that pregnancy is the most common cause of
acute kidney injury in women of childbearing age,60 the
urgency to monitor disease progression in preeclampsia,
possibly by urinary AGT as a marker of inappropriately
activated intrarenal RAS, is underscored. A timely delivery,
also for renoprotective reasons, followed by possible thera-
peutic measures to prevent further renal injury could decrease
women’s risk for future renal and cardiovascular disease.
To the best of our knowledge, this study is the first to
investigate, both functionally and histologically, intrarenal AGT
in normal and hypertensive human pregnancies. While
accepting the limitations on availability of renal biopsy
specimens, similar samples are unlikely ever to be obtained
again. The renal biopsy study in which these samples were
procured showed no renal disease as an underlying cause of
preeclampsia. They also showed the typical lesion of
“endotheliosis” to be present in some normal pregnant
controls, thus no clinical indication remains for performing a
renal biopsy to diagnose renal disease or preeclampsia in
pregnancy in either a clinical or research setting.
These results indicate the presence of intrarenal AGT in
renal tissue from women with GH and preeclampsia and
increased urinary AGT and potassium excretion in our unique
set of matched urine samples. The findings suggest inappro-
priately increased intrarenal RAS activation, seemingly asso-
ciated with glomerular swelling as an indication of
endotheliosis. These changes are likely to be independent
of the systemic renin-angiotensin status. An inappropriately
activated RAS can lead to renal injury through renal
vasoconstriction and numerous other mechanisms, including
activation of the complement system. Apart from a timely
delivery, other therapeutic measures should be considered to
limit damage to the maternal kidneys. Even if treatment were
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available only in the immediate postpartum period, it might
attenuate the risk of future renal disease.
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